AI-driven blood analysis may spur cancer detection, Hong Kong prenatal test pioneer says

Yahoo

23-02-2025

Affordable cancer screening may be available to Hong Kong residents within three years, as advances in artificial intelligence (AI) make the early detection of malignant tumours easier and faster, according to the creator of a pioneering prenatal test for Down syndrome.
AI helps researchers recognise patterns in the gene fragments they find in blood plasma, sparking a revolution in the field of epigenetics, or the study of non-mutation behavioural effects on genes, said Professor Dennis Lo Yuk-ming.
The AI-powered method enables researchers to decipher epigenetic signals from DNA samples without the damaging effects of the chemical treatment that destroys 90 per cent of the genetic material, he said.
Do you have questions about the biggest topics and trends from around the world? Get the answers with SCMP Knowledge, our new platform of curated content with explainers, FAQs, analyses and infographics brought to you by our award-winning team.
"My team members and I were asking: is it possible to use some of the AI methods developed for facial recognition [to help us] see things we cannot see?" Lo said during a January 7 interview with the Post. "As it turned out, it is."
Professor Allen Chan Kwan-chee (left) and Professor Dennis Lo Yuk-ming (right) of the Chinese University of Hong Kong on 10 August 2017. Photo: Dickson Lee alt=Professor Allen Chan Kwan-chee (left) and Professor Dennis Lo Yuk-ming (right) of the Chinese University of Hong Kong on 10 August 2017. Photo: Dickson Lee>
Lo's team at the Centre for Novostics at the Hong Kong Science and Technology Park developed an in-house AI system based on the Convolutional Neural Network, a deep learning model that was designed mainly for image recognition. With advances in generative AI tools such as ChatGPT, the company also incorporated the transformer neural network architecture into the system, he said.
Like many biomedical companies at the forefront of drug discovery, diagnostics and treatment, Novostics is diving into the use of AI. Like many companies in Hong Kong and mainland China, the company "has faced challenges" in accessing computing power because of US curbs on access to cutting-edge AI chips.
Professor Dennis Lo Yuk-ming with a chip that could sequence up to 8 million single DNA molecules for genomic research and genetic disease detection, at the Prince of Wales Hospital in Shatin on 20 October 2020. Photo: K. Y. Cheng alt=Professor Dennis Lo Yuk-ming with a chip that could sequence up to 8 million single DNA molecules for genomic research and genetic disease detection, at the Prince of Wales Hospital in Shatin on 20 October 2020. Photo: K. Y. Cheng>
"Fortunately, we still have a pretty good system that we developed over the years", said Lo, a day before he formally took over as president of the Chinese University of Hong Kong (CUHK). "With the difficulty in getting the latest generation of Nvidia chips, we just have to try other chipmakers that can still provide what we need."
Lo's team is developing tests for the early detection of cancers, using a similar method as his pioneering work on using the blood plasma of pregnant women to check for Down syndrome and other genetic disorders.
Nasopharyngeal cancer (NPC), a throat tumour that is common in southern China's Guangdong province, was the first on Lo's target list. Using the cancer's suspected link with the Epstein-Barr virus, Lo developed a test in 2013 for finding it in blood plasma.
Single-use DNA cells for genome sequencing, at the Prince of Wales Hospital in Shatin on 20 October 2020 . Photo: K. Y. Cheng alt=Single-use DNA cells for genome sequencing, at the Prince of Wales Hospital in Shatin on 20 October 2020 . Photo: K. Y. Cheng>
After collecting 20,000 samples over four years, the study concluded in July 2023 that screening for the virus was an effective detection tool for the cancer, helping to slash the mortality rate to a mere 3.7 per cent from 40 per cent, according to Lo. The test is now available in Hong Kong for HK$1,500 (US$192.5).
"Even though Hong Kong's healthcare system is pretty good, 75 per cent of nasopharyngeal cancer was detected late" before the new test was introduced, Lo said.
The use of AI widened the possibilities of finding other cancers even if a virus may not be behind every cancer, because the discovery of each mutation was "like hunting one thing out of a million", he said.
Cirina, which Lo founded in Hong Kong after creating the NPC test, merged in 2017 with Grail, a company in California that speciliased in cancer detection. The merged company developed the Galleri test to screen for more than 50 types of virus-related cancers, a product that was named as one of The Best Inventions of 2022 by Time magazine.
Grail was bought for US$8 billion in 2021 by the biotechnology giant Illumina, based in San Diego. Its multi-cancer test is only available in the US market for US$949 (HK$7,380), and is not covered by most healthcare coverage plans.
Lo's team is trying to make a cheaper version of the test for mainland China and the rest of the world. Novostics has developed a test called Fragma, which can find the DNA fragments of lung cancer cells and liver carcinoma in blood plasma and urine.
In 2023, Lo established a US$200 million venture called Insighta with Nasdaq-listed Prenetics Group to commercialise the Fragma tests. Tencent Holdings invested US$30 million last October in Insighta, valuing the start-up at US$200 million.
Insighta, based at the Hong Kong Science and Technology Park, is conducting large-scale clinical tests of the Fragma process in Hong Kong and mainland China. It aims to eventually offer the test at US$200 (HK$1,565).
Some of the earlier products, such as the test for liver cancer, will "hopefully" be available "in two or three years from now", Lo said. "If we want to do it in a more resource-challenged environment, we need the technology to be cheaper."
This article originally appeared in the South China Morning Post (SCMP), the most authoritative voice reporting on China and Asia for more than a century. For more SCMP stories, please explore the SCMP app or visit the SCMP's Facebook and Twitter pages. Copyright © 2025 South China Morning Post Publishers Ltd. All rights reserved.
Copyright (c) 2025. South China Morning Post Publishers Ltd. All rights reserved.